|
|
Volumn 9, Issue 9, 2010, Pages 668-669
|
|
Potential remains for PPAR-targeted drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEGLITAZAR;
ANTIDIABETIC AGENT;
BALAGLITAZONE;
GFT 505;
INDEGLITAZAR;
INT 131;
MBX 2044;
MBX 8025;
METAGLIDASEN;
MURAGLITAZAR;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;
PIOGLITAZONE;
ROSIGLITAZONE;
UNCLASSIFIED DRUG;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DIABETES MELLITUS;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG RECEPTOR BINDING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TARGETING;
DYSLIPIDEMIA;
EDEMA;
FLUID RETENTION;
FOOD AND DRUG ADMINISTRATION;
FRACTURE;
GLYCEMIC CONTROL;
HUMAN;
INSULIN SENSITIVITY;
METABOLIC DISORDER;
NON INSULIN DEPENDENT DIABETES MELLITUS;
OBESITY;
PRIORITY JOURNAL;
PROTEIN PHOSPHORYLATION;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
SIDE EFFECT;
WEIGHT GAIN;
CLINICAL TRIAL (TOPIC);
DIABETES MELLITUS, TYPE 2;
DRUG DELIVERY SYSTEM;
DRUG DESIGN;
DRUG EFFECTS;
METABOLISM;
PATHOPHYSIOLOGY;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS, TYPE 2;
DRUG DELIVERY SYSTEMS;
DRUG DESIGN;
HUMANS;
HYPOGLYCEMIC AGENTS;
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;
|
|
EID: 77956335013
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3271 Document Type: Short Survey |
|
Times cited : (41)
|
|
References (0)
|
